Alzheimers
disease is a degenerative memory disorder that affects millions of people
yearly and unfortunately there is no known cure for it.
Currently, we
have an ample knowledge of this subject. Alzheimer's is an irreversible, progressive brain disorder that slowly
destroys memory and thinking skills and, eventually, the ability to carry out
the simplest tasks (n.d). In most people with Alzheimer’s, symptoms first
appear in their mid-60s. The damage initially appears to take place in the
hippocampus, the part of the brain essential in forming memories. As more
neurons die, additional parts of the brain are affected. By the final stage of
Alzheimer’s, damage is widespread, and brain tissue has shrunk significantly (n.d).
Because
of the detrimental and rapid effects of this disease, scientists have been attempting
to find new approaches to treating it. TIME magazine’s journalist Alice Park
Wrote an article titled “Alzheimer from a New Angle”, which presents Dr. Frank
Longo’s, A neurologist at the Stanford University School of Medicine, collected
data about his new form of treatment to tackle it. He states, “For decades, scientists
have pursued a cure with a nearly single-minded focus on how to treat the
disease: by trying to get rid of the hallmark feature of Alzheimer’s, which is
sticky, insidious protein plaques of amyloid that they have fought so well in
mice”, (Park, 2016). So, instead of going the same route as all the rest he
created a pill
called LM11A-31 which does not target the amyloid at all (Park, 2016). Instead
Dr. Longo’s treatment is simply to keep brain cells strong, protected against
neurological onslaughts, whether they’re the effects of amyloid or other
factors involved in Alzheimer’s.
Through
several trials on both mice and human brains, the data he recorded demonstrates
significant improvement in people who have already acquired the disease full on
and in those who are at its onset of symptoms. LM11A-31 may become the first
drug in this new Alzheimer’s cocktail; the results of the first studies among
72 healthy people who don’t have any signs of the disease are promising (Park,2016). The next step is to see if it can make any difference in their memory
and thinking.
The
article reaches a very detailed analysis that would be beneficial to read to fully
understand the proficiency of this new drug.
The
study itself does have a few setbacks. First in the sample size which so far is
relatively small as well as confounding variables which depend on the person’s
health and mental capacity.
Nonetheless,
Dr. Longo’s approach demonstrates that it is always a good idea to take the
road less traveled by. His ability to see different angles for such a complex
problem brings all those suffering from the disease hope that a cure or at
least an improvement in the quality of their lives is just around the corner. This
information is pertinent to a general public because Alzheimer affects 1 in
every 4 people and your chances of having it increase with age.
The
only question left unanswered by this is when is this horrible disease going to
finally see an end?
References:
About
Alzheimer's Disease: Alzheimer's Basics. (n.d.). Retrieved May 01, 2016, from https://www.nia.nih.gov/alzheimers/topics/alzheimers-basics
Park,
A. (2016, February 11). Alzheimer's from a New Angle. Retrieved May 01, 2016,
from http://time.com/4217067/alzheimers-from-a-new-angle/